Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.
Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI’s active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services.
Cristina Green, Vice President of Clinical Research, shared her enthusiasm for this partnership, stating, “This collaboration with Massive Bio complements our ability to connect patients with advanced cancer therapies and cutting-edge clinical trials. By leveraging AI-driven precision medicine, we are confident that this partnership will accelerate breakthroughs in cancer research and deliver life-changing treatment options to our patients.”
“We are incredibly excited about joining forces with The Oncology Institute,” said Selin Kurnaz, Ph.D., CEO of Massive Bio. “This partnership will not only revolutionize cancer care but will also empower patients with access to the most advanced precision medicine available. Our combined expertise will open new doors for patients, connecting them to potentially life-saving treatments and groundbreaking clinical trials.”
Furthermore, this collaboration will expand the scope of cancer research through Massive Bio’s recent ChatGPT-powered chatbots for oncology research release during ASCO 2023. Dr. Arturo Loaiza-Bonilla, renowned oncologist and a key figure in the development of the chatbot technology, stated, “We are proud to be part of this innovative partnership between Massive Bio and TOI. The integration of AI-driven chatbots with clinical decision-support tools will revolutionize the way researchers access and analyze oncology data, enabling more efficient and impactful research initiatives, and will bolster this newly forged alliance to the betterment of all cancer patients.”
The alliance between Massive Bio and TOI represents a paradigm shift in cancer care, combining the power of advanced AI technology, personalized therapy, and an extended network of research collaborations. Together, these industry leaders are poised to reshape the future of oncology and bring new hope to patients and their families.